Company Filing History:
Years Active: 2025
Title: The Innovative Mind of Eric Jeffery: Pioneering Antibody Research in Seattle
Introduction
Eric Jeffery, a notable inventor based in Seattle, Washington, has made significant contributions to the field of immunotherapy through his groundbreaking work in antibody research. With one patent to his name, he is at the forefront of developing revolutionary treatments targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). His innovative insights have the potential to reshape therapeutic approaches in cancer treatment.
Latest Patents
Eric Jeffery's patent, titled "Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)," focuses on receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules. This includes human antibodies that are specifically engineered to bind to ROR1, as well as their fragments. His work further encompasses recombinant receptors that feature chimeric antigen receptors (CARs) containing these antibodies or fragments, alongside polynucleotides that encode the antibodies and antigen-binding fragments. Notably, his advancements contribute to the creation of genetically engineered cells containing ROR1-binding proteins and receptors, which are essential for enhancing adoptive cell therapy methods.
Career Highlights
Throughout his career, Eric Jeffery has established himself as a key figure in his field. He currently works with Juno Therapeutics GmbH, a company that is dedicated to developing innovative cancer immunotherapies. His expertise and pioneering spirit have enabled him to push the boundaries of what is possible in medical research and treatment.
Collaborations
In his pursuit of advancement in immune-oncology, Eric collaborates with esteemed colleagues such as Andreia Costa and Rupesh Amin. Their combined expertise contributes to the enrichment of research and development endeavors aimed at addressing complex medical challenges through innovative solutions.
Conclusion
Eric Jeffery's contributions to the field of antibody research reflect a deep commitment to improving therapeutic outcomes for patients, particularly in cancer treatment. As he continues to break new ground with his patent and collaborative efforts, the impact of his work is likely to resonate within the medical community and beyond, paving the way for future innovations.